Treatment of metastatic clear-cell or papillary renal carcinoma with orellanine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label phase I/II study evaluates the safety, tolerability, and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma. The trial will enroll up to 50 patients, starting with a dose escalation phase followed by a dose exposure phase. In the second phase, an additional 30 patients will be recruited to further assess the drug's safety and efficacy. The study aims to provide insights into a new treatment option for patients with limited conventional therapies available.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Has provided written informed consent.
2. Has a diagnosis of histologically confirmed advanced ccRCC or pRCC. No conventional therapy is available or considered appropriate by the treating physician or is declined by the patient.
3. For patients in the expansion portion of the study only: Measurable disease per RECIST version 1.1 criteria.
4. ECOG performance status of 0 - 2.
5. Age ≥18 years.
6. Life expectancy ≥3 months.
7. Has acceptable haematologic laboratory values defined as:

   1. Neutrophils ≥1.5 × 10\^9/L, without growth factor stimulation within 3 weeks prior to the blood test;
   2. Platelets ≥100 × 10\^9/L;
   3. Haemoglobin ≥5.6 mmol/L (\~90 g/L). Use of erythropoietin or blood transfusions are permitted.
8. Has acceptable liver laboratory values defined as:

   1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for patients with liver metastases
   2. Total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels \>1.5 × ULN
   3. For patients diagnosed with Gilbert's syndrome, total bilirubin ≤2 × ULN is acceptable.
9. Must be on chronic hemodialysis (on a consistent regimen for the previous three months, with allowance for intermittent treatments as required for volume overload).
10. The patient's treating nephrologist and oncologist agree that the prospect of loss of remaining renal function resulting from this treatment will not significantly change the patient's future and chronic dialysis treatment.
11. Female patients of child-bearing potential and male patients must agree to use 2 forms of highly effective contraception for the duration of study treatment and after the last dose of orellanine for at least 3 months for males and 6 months for females.
12. For females of child-bearing potential, a negative serum pregnancy test at screening.
13. Patients who are willing and able to comply with travel requirements, scheduled visits, treatment schedule, efficacy assessments, laboratory tests, and other study procedures.

Exclusion criteria:

1. Diagnosis of any other malignancy within 2 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, superficial melanoma, or carcinoma in situ of the breast or of the cervix, or low grade (Gleason 7 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration)
2. Radiotherapy within 2 weeks before first dose.
3. Immuno-oncology therapy (IO) given in the last six (6) months prior to enrolment
4. Other systemic anti-cancer therapy within 2 weeks before first dose.
5. Has not recovered from AEs due to prior anti-cancer medications to at least grade 1 by CTCAE version 5.0 (except for alopecia and grade 2 neuropathy).
6. Has received any other investigational product within 4 weeks before first dose.
7. Pregnant or breastfeeding women.
8. Uncontrolled medical condition including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, or would, in the opinion of the investigator, place the patient at increased risk.
9. QTc interval at baseline of ≥470 msec.

Where it's running

• University of California Irvine
  Orange, California, United States Recruiting
• Stanford
  Palo Alto, California, United States Recruiting
• University of California San Francisco
  San Francisco, California, United States Recruiting
• Washington University in St. Louis
  St Louis, Missouri, United States Recruiting
• Roswell Park Comprehensive
  Buffalo, New York, United States Recruiting
• University of Texas - MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Hanjing Xie, Ph.D.
• Email: hanjing.xie@oncorena.com
• Phone: +46737031615

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belzutifan plus zanzalintinib versus belzutifan alone for advanced renal cell carcinoma

  This trial tests whether adding the targeted drug zanzalintinib to belzutifan helps people with advanced renal cell carcinoma live longer and delay tumor growth compared with belzutifan plus placebo.

  Recruiting at 107 sites Phase 3 Merck Sharp & Dohme LLC · Duarte, California and 110 other locations · NCT07489495

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• Deep-learning tool to distinguish T1–T2 from T3 renal cell carcinoma on contrast-enhanced CT.

  This project will see if a computer model can tell whether kidney cancer is early (T1–T2) or locally advanced (T3) using contrast-enhanced CT scans before surgery.

  Recruiting Peking University First Hospital · Beijing · NCT07166445

• Using vorolanib for treating advanced kidney cancer

  This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT06676527

• Evaluating bicalutamide and sunitinib for advanced kidney cancer

  This study is testing if a combination of two medications, bicalutamide and sunitinib, can help people with advanced kidney cancer who have not responded to previous treatments.

  Recruiting Phase 1/2 State University of New York at Buffalo · Buffalo, New York · NCT06222593

• Analyzing genetic mutations in kidney cells of patients with Von Hippel-Lindau disease

  This study looks at whether kidney cells from people with Von Hippel-Lindau disease have more genetic changes compared to those without the condition.

  Recruiting IRCCS San Raffaele · Milan · NCT06194669

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.